This study will test an investigational drug called AL001 for the treatment of individuals who have a progranulin gene mutation that causes frontotemporal dementia (FTD). Participation may last up to 2 years.
You may be eligible to participate if you have a progranulin gene mutation and have been diagnosed with FTD (we call this group of people symptomatic participants). You may also be eligible to participate if you have a progranulin gene mutation but are not diagnosed with FTD and have an increased level of a biomarker called neurofilament light chain (NfL) [we call this group of people pre-symptomatic participants].
General Inclusion Criteria:
18 to 85 years of age, inclusive, at screening
At screening, female participants must be nonpregnant and nonlactating
Has availability of a person (study partner) who has frequent and sufficient contact with the participant (at least 5 hours per week of in-person contact), can provide accurate information regarding the participant's behavior, cognitive, and functional abilities as well as their health throughout the study
Exclusion Criteria:
Has dementia due to a condition other than FTD including, but not limited to, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, Huntington disease, or vascular dementia